MRKMerck Sharp & Dohme LLCFinished
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 738 (final count)
- Started
- Oct 5, 2018
- Main results expected
- Mar 20, 2024
- Fully finished
- Nov 12, 2025
- Results posted
- Mar 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR
Measured over: Up to 46 months
Overall Survival (OS)
Measured over: Up to 63 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03615326 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC